A new therapeutic option for the treatment of pneumonia

American Journal of Medicine

Volumn 100, Issue 6 A, 1996, Pages 60S-67S

  McCabe, Robert ^a,b,c   Chirurgi, Valerie ^a,b   Farkas, Stephen A ^c,d,e   Haddow, Alastair ^f   Heinz, George ^f   Greene, Stan ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Martinez VAOPC   (United States)

^c HIGHLAND HOSPITAL   (United States)

^d Fairmont Hospital   (United States)

^e Barberton Citizens Hospital   (United States)

^f St John's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE;

ADULT; AGED; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ANXIETY; BACTERIAL PNEUMONIA; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; ACUTE DISEASE; ARTICLE; CANADA; COMPARATIVE STUDY; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; PUERTO RICO; UNITED STATES;

ACUTE DISEASE; AGED; CANADA; CEFTAZIDIME; CEPHALOSPORINS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PUERTO RICO; UNITED STATES;

EID: 0030600091     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(96)00109-x     Document Type: Conference Paper

References (27)

1. Fang GD, Fine M, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy. Medicine. (Baltimore) 1990;69:307-316.
2. Scheld WM, Mandell GL. Nosocomial pneumonia: pathogenesis and recent advances in diagnosis and therapy. Rev Infect Dis. 1991;13(suppl 9):S743-S751.
3. Toye BW, Scriver SR, Low DE, and The Canadian Antimicrobial Resistance Study Group. Canadian survey of antimicrobial resistance in Klebsiella spp. and Enterobacter spp. J Antimicrob Chemother. 1993;32(suppl B):81-86.
4. Yee YC, Thornsberry C, Brown SD, Bouchillon SK, Marler JK, Rich T. A comparative study of the in-vitro activity of cefepime and other antimicrobial agents against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 1993;32(suppl B):13-19.
5. Applebaum PC. Antimicrobial resistance in Streptococcus pneumoniae; an overview. Clin Infect Dis. 1992;15:77-83.
6. Barckow D, Schwigon C-D. Cefepime versus cefotaxime in the treatment of lower respiratory tract infections. J Antimicrob Chemother. 1993;32(suppl B):187-193.
7. Jones RN. The current and future impact of antimicrobial resistance among nosocomial bacterial pathogens. Diag Microbiol Infect Dis. 1992;15(suppl 2):3S-10S.
8. Bodey GP, Ho DH, LeBlanc B. In vitro studies of BMY-28142, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1985;27:265-269.
9. Phelps DJ, Carlton DD, Farrell CA, Kessler RE. Affinity of cephalosporins for β-lactamases as a factor in antibacterial efficacy. Antimicrob Agents Chemother. 1986;29:345-348.
10. Grassi GG, Grassi C. Cefepime: overview of activity in vitro and in vivo. J Antimicrob Chemother. 1993;32(suppl B):87-94.
11. Kovarik J, Rozenberg-Arska M, Visser M, Verhoef J. Pharmacodynamics of cefepime. Scand J Infect Dis. 1991;74(suppl):270-273.
12. Okamoto MP, Nakahiro RK, Chin A, Bedikian A. Cefepime clinical pharmacokinetics. Clin Pharmacokinet. 1993;25:88-102.
13. Thornsberry C, Brown SD, Yee YC, Bouchillon SK, Marler JK, Rich T. In-vitro activity of cefepime and other antimicrobials: survey of European isolates. J Antimicrob Chemother. 1993;32(suppl B):31-53.
14. Cunha BA, Gill MV. Cefepime. Med Clin North Am. 1995;79:721-723.
15. Fung-Tomc J, Huczko E, Pearce M, Kessler RE. Frequency of in vitro resistance of Pseudomonas aeruginosa to cefepime, ceftazidime, and cefotaxime. Antimicrob Agents Chemother. 1988;32:1443-1445.
16. Kessler RE, Fung-Tomc J. Susceptibility of bacterial isolates to β-lactam antibiotics from U.S. clinical trials over a 5-year period. Am J Med. 1996;100(suppl 6A):13S-19S.
17. Neu HC, Chin NX, Jules K, Labthavikul P. The activity of BMY-28142, a new broad spectrum β-lactamase stable cephalosporin. J Antimicrob Chemother. 1986;17:441-452.
18. Barbhaiya RH, Forgue ST, Gleason CR, et al. Pharmocokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob Agents Chemother. 1992;36:552-557.
19. Chadha D, Wise R, Baldwin DR, Andrews JM, Ashby JP, Honeybourne D. Cefepime concentrations in bronchial mucosa and serum following a single 2 gram intravenous dose. J Antimicrob Chemother. 1990;25:959-963.
20. Edelstein H, Chirurgi V, Oster S, et al. A randomized trial of cefepime (BMY-28142) and ceftazidime for the treatment of pneumonia. J Antimicrob Chemother. 1991;28:569-575.
21. Leophonte P, Bertrand A, Nouvet G, Muir JF, Lucht F, Delaval P, et al. A comparative study of cefepime and ceftazidime in the treatment of community-acquired lower respiratory tract infections. J Antimicrob Chemother. 1993;32(suppl B):165-173.
22. Hoepelman AIM, Kieft H, Aoun M, et al. International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections. J Antimicrob Chemother. 1993;32(suppl B):175-186.
23. Tsuji A, Maniatis A, Bertram MA, Young LS. In vitro activity of BMY-28142 in comparison with those of other β-lactam antimicrobial agents. Antimicrob Agents Chemother. 1985;27:515-519.
24. Korvick JA, Yu VL. Antimicrobial agent therapy for Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1991;35:2167-2172.
25. Gouin F, Papazian L, Martin C, et al. A non-comparative study of the efficacy and tolerance of cefepime in combination with amikacin in the treatment of severe infections in patients in intensive care. J Antimicrob Chemother. 1993;32(suppl B):205-214.
26. Eggiman P, Glauser MP, Aoun M, et al. Cefepime monotherapy for the empirical treatment of fever in granulocytopenic cancer patients. J Antimicrob Chemother. 1993;32(suppl B):151-163.
27. Kieft H, Hoepelman AIM, Knupp CA, et al. Pharmacokinetics of cefepime in patients with the sepsis syndrome. J Antimicrob Chemother. 1993;32(suppl B):117-122.